Archives

Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029

B FY’26 total reported revenue from continuing operations to range between approximately $603 to $621 million FY’26 organic revenue is now expected to range from… Login to continue reading Login…

Read MoreAzenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029

Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients

B Regulatory Clearance in Spain Advances Randomized, Placebo-Controlled Study; Patients Show Meaningful Reductions in EGFR-Inhibitor Skin Toxicities with No Treatment Disruptions Array NEW YORK, May 5,… Login to continue reading Login…

Read MoreHoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients

Factor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting

B -Factor advances next-generation allogeneic and in vivo CAR-T cell therapy programs -Presentations will include latest data from Factor’s IL12-expressing iMacrophages for treating solid tumors… Login to continue reading Login…

Read MoreFactor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting